A B S T R A C T

Background
Pulse oximetry could contribute to the evaluation of fetal well-being during labour.
Objectives
To compare the effectiveness and safety of fetal pulse oximetry with conventional surveillance techniques.
Search strategy
We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (November 2006) , MEDLINE (1994 to November 2006 , EMBASE (1994 to November 2006 and Current Contents (1994 ( to November 2006 .
Selection criteria
All published and unpublished randomised controlled trials that compared maternal and fetal outcomes when fetal pulse oximetry was used in labour, with or without concurrent use of conventional fetal surveillance, compared with using cardiotocography (CTG) alone.
Data collection and analysis
At least two independent authors performed data extraction. Analyses were performed on an intention-to-treat basis. We sought additional information from the investigators of three of the reported trials.
Main results
Five published trials comparing fetal pulse oximetry and CTG with CTG alone (or when fetal pulse oximetry values were blinded) were included. The published trials, with some unpublished data, reported on a total of 7424 pregnancies. Differing entry criteria necessitated separate analyses, rather than meta-analysis of all trials.
Four trials reported no significant differences in the overall caesarean section rate between those monitored with fetal oximetry and those not monitored with fetal pulse oximetry or for whom the fetal pulse oximetry results were masked. Neonatal seizures and hypoxic ischemic encephalopathy were rare. No studies reported details of assessment of long-term disability.
There was a statistically significant decrease in caesarean section for nonreassuring fetal status in the fetal pulse oximetry plus CTG group compared to the CTG group in two analyses: (i) gestation from 36 weeks with fetal blood sample (fetal blood sampling) not required prior to study entry (relative risk (RR) 0.68, 95% confidence interval (CI) 0.47 to 0.99); and (ii) when fetal blood sampling was required prior to study entry (RR 0.03, 95% CI 0.00 to 0.44). There was no statistically significant difference in caesarean section for dystocia when fetal pulse oximetry (fetal pulse oximetry) was added to CTG monitoring, compared with CTG monitoring alone, although the incidence rates varied between the trials.
Authors' conclusions
The data provide limited support for the use of fetal pulse oximetry when used in the presence of a nonreassuring CTG, to reduce caesarean section for nonreassuring fetal status. The addition of fetal pulse oximetry does not reduce overall caesarean section rates. A better method to evaluate fetal well-being in labour is required.
P L A I N L A N G U A G E S U M M A R Y
Using fetal pulse oximetry to assess the baby's well-being during labour does not change overall caesarean section rates During labour, the well-being of the baby can be assessed intermittently using a Pinard stethoscope or hand held monitor, or continuously using cardiotocography (CTG, sometimes called electronic fetal monitoring, EFM) or assessing the baby's condition with an electrocardiogram (ECG). There are also additional tests that can be used if the baby is thought to be getting short of oxygen, like testing the baby's blood in a sample taken from the baby's head or bottom. A new method, fetal pulse oximetry, measures how much oxygen the baby's blood is carrying. It uses a probe that sits inside the vagina during labour. The probe is said not to inhibit the woman's mobility during labour. This review looked at fetal pulse oximetry and only found trials that used it in conjunction with a CTG and compared the combined use with CTG alone. The review identified five trials involving 7424 women. Fetal pulse oximetry plus CTG showed no difference in caesarean section rates overall, nor any difference in the mother's or newborn's health, compared with CTG alone. If there was concern about the baby's well-being before the fetal pulse oximetry probe was placed, the use of fetal pulse oximetry reduced caesarean sections performed for the baby's well-being. In one of the trials, the company making the fetal pulse oximetry machines provided some funding. Further trials may be helpful.
B A C K G R O U N D
Cardiotocography (CTG), was introduced in the 1960s with the aim of improving neonatal outcomes by improving intrapartum fetal surveillance. Fetal heart rate patterns may be classified as reassuring, nonreassuring or abnormal, based on the rate, variability and decelerations, and to some extent comparing these to the timing of uterine contractions. There are several published guidelines for the interpretation of these patterns (for example, RANZCOG 2002; RCOG 2001) . Reassuring patterns require no specific action. Nonreassuring patterns occur in about 15% of labours monitored by CTG (Umstad 1993) and may prompt clinical actions ranging from simple manoeuvres, such as a change of maternal position, through to expedited birth of the baby (vacuum, forceps, caesarean section). Abnormal patterns usually prompt expedited birth with the aim of preventing or minimising hypoxia in the fetus. The positive predictive value of CTG for adverse outcome is low and the negative predictive value high (Umstad 1993), although this is improving with computerised interpretation of CTGs (Strachan 2001) . Thus, while a normal CTG usually indicates reassuring fetal status, a nonreassuring or abnormal CTG does not necessarily equate with 'fetal distress'. These features, combined with marked inter-observer variation in CTG interpretation by midwives (Devane 2005) and doctors (Palomaki 2006) , result in variable but inappropriately high operative delivery rates for nonreassuring fetal status in many hospitals. Electronic fetal monitoring rapidly gained widespread acceptance for monitoring the fetal heart rate during labour, but it was not until the 1970s that randomised controlled trials were conducted to assess the benefits of this technology. A Cochrane systematic review found that the use of electronic monitoring increased the odds of having a caesarean section, compared to intermittent auscultation of the fetal heart (Alfirevic 2006). Despite these shortcomings, cardiotocography remains a widely used means of assessing fetal well-being during labour. One conclusion of the systematic review of CTG monitoring was to consider how to best convey the uncertainty of the benefits of such monitoring to enable women to make an informed choice, while not compromising labour normality (Alfirevic 2006) . The Royal College of Obstetricians and Gynaecologists (RCOG 2001) suggested that, as for all aspects of care, the woman herself should be involved in decision-making for choice of fetal monitoring, with adequate access to evidence-based information; and recommended that electronic monitoring be offered where there is an increased risk of perinatal death, neonatal encephalopathy or cerebral palsy, and during labours induced or augmented by oxytocin.
Once a nonreassuring fetal heart rate pattern has been identified, a number of additional assessments of fetal well-being may be considered. These do not replace the CTG, but are usually used as complementary to it, either intermittently or continuously. One example is fetal scalp blood sampling for pH or lactate analysis. A low pH (for example, less than 7.20) or a high lactate (for example greater than 4.8 mmol/L) may be considered abnormal (Kruger 1999) . The addition of fetal scalp blood sampling to standard electronic monitoring reduces the odds for caesarean section, although the odds are not significantly different compared to intermittent auscultation of the fetal heart (Alfirevic 2006). A Cochrane systematic review of the addition of fetal electrocardiogram monitoring reported no difference in overall caesarean section rate when compared to electronic monitoring only (Neilson 2006) .
Fetal pulse oximetry is a new technology aimed at improving the accuracy of the evaluation of fetal well-being during labour (Colditz 1999; East 2002) . It is generally reserved for use when a nonreassuring CTG has been recorded, to assist in identifying those fetuses that may benefit from further intervention (East 2002) and as an adjunct to, rather than replacement of, the CTG monitor. This method has two potential advantages over conventional fetal heart rate monitoring: (i) it directly measures the proportion of haemoglobin that is carrying oxygen: thus, oxygena-tion, the primary variable underlying the tissue damaging effects of hypoxia/ischaemia is being monitored; and (ii) it relies on an established, safe, noninvasive, widely-used technology found in every modern intensive care unit and operating theatre. A variety of fetal pulse oximetry sensors has been studied. These are placed during a vaginal examination to attach to the top of the fetal head by suction (Arikan 2000) Results of animal and human research suggest that when using sensors calibrated for the fetal environment, fetal oximetry values greater than or equal to 30% are considered reassuring, even when the CTG is nonreassuring, while values less than 30% warrant consideration of interventions, ranging from maternal position change, through to urgent birth via caesarean section (Kuhnert 1998; Nijland 1995; Seelbach-Gobel 1999) . One manufacturer recommends this technology for singleton pregnancies only (Nellcor 2004) . Consideration for monitoring multiple pregnancies by monitoring the first fetus during labour, then the second or subsequent fetuses following birth of the preceding fetus may be possible. Women have rated their experience with fetal oximetry during observational studies. One survey included questions about the woman's perceived level of comfort during sensor placement, mobility with the sensor in place and ongoing comfort with the sensor in place: these factors were all rated favourably by the women (East 1996) . Arikan 1998 reported that the majority of women did not consider that a fetal oximetry sensor restricted their movement during labour.
The value of any fetal monitoring system during labour, including the CTG or any additional surveillance, is usually expressed by its ability to predict which fetuses are hypoxic or acidotic. Measures of this may include umbilical cord blood gases (including base excess values less than or equal to 12 mmol/L and pH values less than 7.00 (Sehdev 1997), or less than 7.10 (Arikan 2000) or lactate values; or clinical outcomes including Apgar scores (an assessment of neonatal condition shortly after birth, usually at one and five minutes: Apgar scores of less than seven at five minutes or later are nonspecific but may be associated with hypoxia (MacLennan 1999; Sehdev 1997)); or abnormal neurological status of the baby, possibly caused by lack of oxygen or blood supply (hypoxicischaemic encephalopathy), or both. Other outcomes of interest may include fetal/maternal infections, for example of the membranes (chorioamnionitis), or the uterine lining (endometritis). Interventions resulting from such tests are also important. For example, it is important to note not only overall modes of birth following different forms of monitoring, but also specific interventions, such as operative birth (vacuum, forceps and caesarean section) for the indication of nonreassuring fetal status, since nonreassuring fetal status is what the monitoring is intended to discern. In the longer term, such interventions may also impact on future pregnancies. For example, the likelihood of a successful vaginal birth after caesarean (VBAC) in a subsequent pregnancy is improved for women whose previous caesarean was performed for the indication of nonreassuring fetal status, compared with those where the previous caesarean was performed for dystocia (Grinstead 2004; Shipp 2000) . Successful VBAC in a subsequent pregnancy will also have economic benefits, with vaginal births costing the health system considerably less than caesarean sections (Henderson 2001; Petrou 2002 ).
This review was undertaken to evaluate the clinical effectiveness and safety of fetal pulse oximetry to assess fetal well-being in labour.
O B J E C T I V E S
To compare the effectiveness and safety of fetal intrapartum pulse oximetry with conventional fetal surveillance techniques, using the results of randomised controlled trials.
C R I T E R I A F O R C O N S I D E R I N G S T U D I E S F O R T H I S R E V I E W
Types of studies
All published and unpublished randomised and quasi-randomised trials with reported data that compared maternal and fetal/neonatal/infant outcomes when fetal pulse oximetry was used in labour, with or without concurrent use of conventional fetal surveillance, compared with the use of conventional fetal surveillance techniques alone.
Types of participants
Women in labour with a live baby where fetal monitoring is clinically indicated.
Types of intervention
Use of fetal pulse oximetry compared with not using fetal pulse oximetry, with or without concurrent use of conventional fetal monitoring (fetal heart rate monitoring by intermittent auscultation, intermittent/continuous cardiotocography, or fetal blood sampling for blood gas analysis).
Types of outcome measures
Primary outcomes
(1) Caesarean section (2) Hypoxic-ischaemic encephalopathy (3) Neonatal seizures (4) Long-term neurodevelopmental outcome
Secondary outcomes
Maternal (5) Caesarean section for nonreassuring fetal status (6) Caesarean section for dystocia (added since the protocol and original review were first published) Details of the search strategies for CENTRAL and MEDLINE, the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service can be found in the 'Search strategies for identification of studies' section within the editorial information about the Cochrane Pregnancy and Childbirth Group.
S E A R C H M E T H O D S F O R I D E N T I F I C A T I O N O F S T U D I E S
Trials identified through the searching activities described above are given a code (or codes) depending on the topic. The codes are linked to review topics. The Trials Search Co-ordinator searches the register for each review using these codes rather than keywords.
In addition, we searched MEDLINE (1994 ( to November 2006 , EMBASE (1994 to November 2006 We also sought ongoing and unpublished trials by contacting experts in the field.
We did not apply any language restrictions.
M E T H O D S O F T H E R E V I E W
We used the standard methods of the Cochrane Collaboration as described in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2005) . At least two authors (Chris East (CE), Fung Yee Chan (FYC), Lisa Begg (LB), Paul Colditz (PC)) assessed trials under consideration for appropriateness of inclusion and methodological quality without consideration of their results. LB assessed, in particular, the quality and findings of the trials for which the remaining authors were co-investigators (East 2006) . There were no differences of opinion requiring resolution by an alternative author. Blinding of trial authorship was not undertaken.
Assessment of trial quality
We considered four major sources of potential bias and methods or avoidance of these biases when assessing trial quality: (1) selection bias -allocation concealment; (2) performance biasblinding of intervention; (3) attrition bias -completeness of follow up; (4) detection bias -blinding of outcome assessment. The quality assessment was based on a systematic assessment of the opportunity for each of these biases to arise.
We assigned a quality rating for allocation concealment, using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2005): (A) adequate; (B) unclear; (C) inadequate; or (D) not used. A quality rating of (A) = yes; (B) = cannot tell; or (C) = no, was assigned to the other quality components (blinding of intervention, completeness of follow up and blinding of outcome assessment).
We made an a priori decision to exclude trials where outcome data were unavailable for more than 20% of participants.
Data management
We sought additional information from the authors of three trials (see 'Characteristics of included studies' table).
At least two independent authors (CE, FYC, LB, PC) performed data extraction and any disagreements were to have been resolved by discussion with an alternative author. There were no disagreements. Analyses were performed on an intention-to-treat basis.
We reported mean differences (and 95% confidence intervals) for continuous variables with reported data. For categorical outcomes, the relative risks (and 95% confidence intervals) were reported.
Data analysis
The differences in entry criteria for the reported studies made combined statistical analysis problematic. We addressed this by considering the following analyses:
(A) nonreassuring fetal heart rate prior to study entry: (i) gestation from 36 weeks, fetal blood sampling (fetal blood sampling) not required prior to study entry; (ii) gestation from 36 weeks, fetal blood sampling prior to study entry; (iii) gestation from 28 weeks, fetal blood sampling not required prior to study entry; and (B) gestation from 36 weeks, nonreassuring fetal status not required prior to study entry.
Sensitivity analyses were conducted to evaluate the effect of trial quality: separate analysis of different types of studies within each outcome allowed inclusion of all identified studies, regardless of trial quality. Heterogeneity was addressed by the use of separate analyses of different types of studies within each analysis and random-effects modelling.
We planned subgroup analyses, to be conducted separately for singleton and multiple pregnancies as data permitted, as follows. Fetal pulse oximetry compared with: (i) fetal heart rate monitoring by:
• intermittent auscultation;
• intermittent cardiotocography;
• continuous cardiotocography;
• continuous cardiotocography and fetal scalp stimulation;
• continuous cardiotocography and fetal electrocardiogram (ECG) analysis (ST segment);
• continuous cardiotocography and fetal ECG analysis (PR interval); and (ii) fetal blood sampling for blood gas analysis.
Several trials indicated that fetal blood sampling was performed (East 2006; Garite 2000; Kuhnert 2004 ). However, data were only available to allow for one of these to be included in a subgroup analysis (East 2006) . None of the remaining subgroup analyses were conducted, as we were unable to identify trials that addressed these questions.
D E S C R I P T I O N O F S T U D I E S
See 'Characteristics of included studies' Kuhnert 2004 reported a trial from Germany which compared operative delivery and fetal scalp blood sampling for nonreassuring fetal status in two groups: those with CTG monitoring and those with fetal pulse oximetry added to the CTG, for a total of 146 cases. Fetal blood sampling was required prior to study entry. Whilst not stated in the report, it is appropriate to consider that if the scalp pH was nonreassuring, intervention would have been undertaken to correct this or to deliver the baby prior to enrollment in the study. It can therefore be considered that this represents, at least in part, a different study population to that of the other studies.
A single-centre trial from the USA, reported by Klauser 2005, included 327 women with gestation from 28 weeks onward. This study compared caesarean delivery for nonreassuring fetal status in women with and without fetal pulse oximetry added to CTG monitoring (Klauser 2005) . Interpretation of fetal heart rate monitoring is different in premature babies, compared with term babies. The report did not allow the reader to distinguish outcomes by gestational age. It may therefore be appropriate to consider that this represents a heterogenous population. This would make subsequent combination with other trials inappropriate. We were unable to contact the authors to consider analysis by gestation.
An Australian multicentre trial compared operative delivery for nonreassuring fetal status in those with and without fetal pulse oximetry added to CTG monitoring (East 2006) on 600 pregnancies.
The trial reported by Bloom 2006 included 2168 women with a nonreassuring CTG at the time of study entry, of the 5341 enrolled in the study overall (see below).
Trials with nonreassuring fetal status not required prior to study entry Bloom 2006 reported a multicentre trial conducted in the USA (n = 5341), which enrolled nulliparous women with CTG monitoring in labour. All participants had a fetal pulse oximetry sensor placed and were then randomly allocated to the 'open' arm with fetal pulse oximetry values displayed or the 'masked' arm with fetal pulse oximetry values stored to computer disk and not displayed to the woman or clinician. These results were analysed separately from the other studies, as the study population, labouring women with a CTG, could not be considered in the same manner as those with a nonreassuring CTG. The report included limited outcomes for a separate analysis of those with a nonreassuring CTG prior to study entry.
No unpublished studies were found.
M E T H O D O L O G I C A L Q U A L I T Y
The published studies were unblinded (in terms of group allocation), randomised controlled trials (trials), with complete follow up. The 'masked' group in the study by Bloom 2006 meant that the labouring woman and clinicians were blinded to fetal oximetry values. Outcome assessment of all trials was unblinded with the exception of (i) a post hoc analysis of partograms in the trial by Garite 2000, constructed to demonstrate progress in labour for all cases of dystocia (defined) and failed induction of labour (defined), for which the review author was blinded to group allocation and (ii) review of women's records in the study reported by Bloom 2006 when the initial data indicated the presence of a placental abruption, prolonged fetal heart rate deceleration at the time of sensor insertion and serious neonatal outcomes, including death or five minute Apgar score less than four.
Women in labour at greater than or equal to 28 (Klauser 2005) or 36 weeks' gestation (East 2006; Garite 2000; Klauser 2005) who gave informed consent and whose fetuses displayed nonreassuring heart rate traces, were randomised to conventional cardiotocography monitoring, or to the addition of fetal pulse oximetry. Management of fetal heart rate patterns and fetal pulse oximetry followed an algorithm. In contrast to the other reported trials, the study by Bloom 2006 did not require nonreassuring fetal status prior to study entry. The 'masked' group of this trial is treated in this review as 'cardiotocography-only' for the purposes of metaanalysis, since the fetal pulse oximetry values did not influence clinical decisions. The primary outcome for each trial was caesarean section or overall operative birth for nonreassuring fetal status. See 'Characteristics of included studies' for further details. Methods of randomisation and allocation concealment were not reported in some studies (Klauser 2005; Kuhnert 2004 ). The reports of the trials by Kuhnert 2004 and by Klauser 2005 were less detailed overall than for the other trials. All trials were included in the meta-analysis to allow a comprehensive representation of the findings. The use of a summary measure of effect for all trials was not used, however, as the appropriateness of combining studies with differing quality, entry criteria and significant heterogeneity if separate analyses were not used, remained uncertain.
R E S U L T S
Five trials involving 7424 participants were included in this review.
Primary outcomes
Four of the five trials reported no significant differences in the overall caesarean section rate between those monitored with fetal oximetry and those not monitored with fetal pulse oximetry or for whom the fetal pulse oximetry results were masked. The smaller study for which fetal blood sampling was required prior to study entry (n = 146) reported a significant decrease in caesarean section in the fetal oximetry group, compared with the control group 
Secondary outcomes: maternal
There was a statistically significant decrease in caesarean section for nonreassuring fetal status in the fetal pulse oximetry plus CTG group compared to the CTG group in two of the four analyses: (i) gestation from 36 weeks with fetal blood sampling not required prior to study entry (relative risk (RR) 0.68, 95% confidence interval (CI) 0.47 to 0.99); and (ii) when fetal blood sampling was required prior to study entry (RR 0.03, 95% CI 0.00 to 0.44).
There was a statistically significant decrease in operative delivery (caesarean section, forceps or vacuum birth) for nonreassuring fetal status when fetal pulse oximetry was added to CTG monitoring, in all three studies that reported this outcome (n = 1756).
There was no statistically significant difference in caesarean section for dystocia when fetal pulse oximetry (fetal pulse oximetry) was added to CTG monitoring, compared with CTG monitoring alone. 
Subgroup analyses
Data were available from one trial (East 2006) to allow the planned subgroup analyses of fetal scalp blood sampling postrandomisation. There were no significant differences in the primary outcome of caesarean section and no seizures were reported for any of the babies in this subgroup. Data were not available to allow the remaining subgroup analyses to be conducted.
D I S C U S S I O N
Four of the five published trials (with some unpublished data available), comparing fetal intrapartum pulse oximetry with CTG or masked fetal pulse oximetry, reported no difference in the overall caesarean section rate between the fetal pulse oximetry group and the CTG group. One smaller study did note a significant difference in favour of the fetal pulse oximetry plus CTG group.
Meta-analysis of the three studies with nonreassuring fetal status from 36 weeks' gestation prior to randomisation, demonstrated a reduction in caesarean section for nonreassuring fetal status, with no differences in neonatal outcomes. That is, a decision not to perform a caesarean section for nonreassuring fetal status in the fetal pulse oximetry group did not result in worse outcomes for those babies (but a larger sample would be required to demonstrate a difference in such low-prevalence outcomes). There were no between-group differences in caesarean section for nonreassuring fetal status when all participants in the largest study were considered, when analysed without consideration of fetal status at study entry.
These findings from over 7000 participants in high-quality studies provide substantial evidence to suggest that knowledge of fetal pulse oximetry values does not influence overall caesarean section rate. However, several issues warrant consideration: (1) Does the indication for caesarean section matter if the overall incidence of caesarean section is the same? (2) Does the presence of a fetal oximetry sensor contribute to dystocia?
The decision pathway leading to performing a caesarean section may be important. The additional information that fetal pulse oximetry can provide, when a nonreassuring fetal heart rate trace has been identified, may translate to avoidance of a caesarean section for nonreassuring fetal status, with its associated stress levels for the mother and resource implications for the health service providers. An 'inevitable' caesarean section may still be performed for other indications, when the woman has had more time to consider her options. Staffing levels can also be adjusted over a number of hours, rather than the immediate and potentially costly provision of staff for an emergency operation. One trial reported that the addition of fetal pulse oximetry to CTG monitoring was costeffective in reducing operative delivery for nonreassuring fetal status (East 2006).
When the findings of the first trials of fetal pulse oximetry became available, there was debate about why the incidence of caesarean section for dystocia more than doubled from 9% in the CTG-only group to 19% when fetal pulse oximetry was added. The investigators explored several possible causes for the increase in dystocia in the fetal pulse oximetry group, including potential mislabelling of dystocia and the presence of the oximetry sensor slowing the labour (Garite 2000). The authors concluded that mislabelling of the indication for caesarean section had not occurred and the presence of the sensor did not result in a longer labour. Safety of fetal pulse oximetry has been partially addressed by the published trials: fetal/neonatal and maternal outcomes were not different in the two groups of monitoring, although power was low for some low prevalence outcomes. Long-term neurodevelopmental outcome has not been measured.
A U T H O R S ' C O N C L U S I O N S
Implications for practice
Is fetal pulse oximetry ready for use in clinical practice? European clinicians published guidelines for fetal pulse oximetry use (Kuhnert 1998; Saling 1996) that were consistent with the management of fetal pulse oximetry in the Garite trial (Garite 2000) and prior to its results being known. Only one small randomised controlled trial of fetal pulse oximetry has since been reported from Europe to test these guidelines (Kuhnert 2004) . That trial did report a significant decrease in both overall caesarean section rate and caesarean section for nonreassuring fetal status when fetal pulse oximetry was added to cardiotocography (CTG) monitoring, compared with CTG only (Kuhnert 2004) . Current data suggest that knowledge of fetal pulse oximetry does not affect overall caesarean section rates.
The American College of Obstetrics and Gynecology (ACOG) reviewed the results of the trial reported by Garite 2000 and recommended further trials before the introduction of fetal pulse oximetry into clinical practice (ACOG 2001). Their recommendation was based mainly on the increase in dystocia reported with the use of fetal pulse oximetry and the potential to increase fetal monitoring costs without improving clinical outcomes (ACOG 2001).
One trial reported that the addition of fetal pulse oximetry to cardiotocography was cost effective in reducing operative delivery for nonreassuring fetal status (East 2006).
The use of CTG has some parallels. Current clinical practice recommendations are that the clinician and the individual woman should consider the appropriateness of CTG to enable an informed choice for each case (Alfirevic 2006; RCOG 2001) . Given the high quality of evidence from several of the reported fetal pulse oximetry trials and the reduction in caesarean section for nonreassuring fetal status (but not for overall caesarean section rates) in those for which a nonreassuring CTG was required prior to study entry, it may be prudent when developing recommendations to encourage the individual woman and her clinicians to make the decision to use or not use fetal pulse oximetry. Unlike CTG, however, the randomised controlled trials of fetal pulse oximetry have been conducted prior to widespread clinical acceptance and medico-legal expectation of fetal pulse oximetry usage where there is concern about fetal well-being.
Commercial availability of the fetal pulse oximetry system used in the five studies was discontinued during 2006. Other systems that
have not yet been subject to trials remain available commercially.
The data provide limited support for the use of fetal pulse oximetry when used in the presence of a nonreassuring CTG, to reduce caesarean section for nonreassuring fetal status. This finding is similar to other tests available to evaluate fetal well-being in labour (fetal scalp blood sampling for pH estimation (Alfirevic 2006) and fetal electrocardiogram (Neilson 2006)), which also do not reduce caesarean sections. A better method to evaluate fetal well-being in labour is required.
Implications for research
Further trials could address: entry criteria related to the severity of nonreassuring CTG patterns; action levels for fetal pulse oximetry values, such as a decline by 10% or 20%, rather than an absolute cut-off value; and the endpoint of long-term neurodevelopmental outcomes. The ideal study to address the issue of dystocia when a fetal pulse oximetry sensor is placed alongside the fetal head would compare caesarean section for dystocia in three groups: those with fetal oximetry displayed, those with fetal pulse oximetry masked and those without fetal pulse oximetry. Further studies using fetal oximetry sensors attached to the fetal scalp, rather than placed alongside the fetal head, could also be considered.
P O T E N T I A L C O N F L I C T O F I N T E R E S T
Three authors (C East, FY Chan, P Colditz) were chief investigators in the Australian multicentre randomised controlled trial of fetal intrapartum pulse oximetry (East 2006). That trial was supported in part by a research grant and equipment loan from Nellcor Inc, manufacturers of a fetal pulse oximetry system. An additional co-author who was not an investigator in that trial, L Begg, joined the review team to evaluate that trial for incorporation in this update of the review.
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T A B L E S
Characteristics of included studies
Study Bloom 2006
Methods RCT.
Quality assessment (see footer): blinding of intervention = women and clinicians blinded to FPO values in the 'masked' group: however, not actually blinded to intervention (C); completeness of follow up = A; blinding of outcome assessment = B, however, if certain outcomes were identified, blinded chart review authors then confirmed the outcomes. Participants Nulliparous women from 36 weeks' gestation with a singleton pregnancy and cephalic presentation, in early labour (2-5 cm cervical dilatation) with ruptured amniotic membranes who gave informed consent. Both groups: standard fetal heart rate monitoring; labour management at the clinician's discretion.
Outcomes Primary: caesarean section (any indication).
Secondary: caesarean section for nonreassuring fetal status or dystocia; "fetal vulnerability index" (stillbirth, neonatal death, 5-min Apgar score less than 3, umbilical pH less than or equal to 7, seizures, admission to neonatal intensive care unit for greater than or equal to 24 hours); other neonatal morbidity.
Notes
Fetal oximetry system used: Nellcor OxiFirst.
Allocation concealment B -Unclear
Study East 2006
Methods Multicentre RCT. Random allocation: telephone randomisation. Survey of women's perceptions: identical surveys to participants in each group within a few days of giving birth and 3 months later. Women were asked to rate their experience in 3 domains: labour (maximum score 12), fetal monitoring (maximum score 16) and participation in research (maximum score 12). Cost-effectiveness analysis the RCT. Costs included diagnosis-related group costs, FBS, medications, use of oxygen or intravenous fluid, or both, FPO. Effect was the primary outcome of the RCT (operative delivery for nonreassuring fetal status).
Quality assessment (see footer): blinding of intervention = C; completeness of follow up = A; blinding of outcome assessment = C. Participants 601 women in labour. 1 exclusion, leaving 600 analysed.
Inclusion criteria: nonreassuring CTG (defined), >= 36 weeks' gestation, early or active labour, ruptured amniotic membranes or eligible for artificial rupture of membranes.
Exclusion criteria: multiple gestations, nonvertex presentation, placenta praevia, abruptio placentae, uterine anomaly, antepartum haemorrhage, fetal anomaly, known significant viral infections (eg HIV), any other contraindications to invasive monitoring such as thrombocytopenia.
Interventions
Control group: fetal heart rate monitoring (CTG) (doppler/fetal scalp electrode).
Intervention group: CTG plus fetal pulse oximetry. Protocol for action with reassuring (>= 30%) and nonreassuring fetal oximetry values (< 30% for 10 minutes, or not recording).
Outcomes
Primary outcome: operative delivery (caesarean section, vacuum, forceps) for nonreassuring fetal status.
Maternal outcomes including: caesarean section and assisted vaginal delivery for nonreassuring fetal status; caesarean and assisted vaginal delivery section for dystocia/failure to progress; caesarean or assisted vaginal birth for combined indication of nonreassuring fetal status and dystocia; caesarean section; assisted vaginal birth; spontaneous vaginal birth; labour interventions and fetal evaluations (eg scalp pH); endometritis; postpartum haemorrhage; length of stay.
Women's perceptions: satisfaction measured in 3 domains: labour, fetal monitoring and participation in research.
Neonatal outcomes including: Apgar scores; umbilical cord blood gases; resuscitation; admission to neonatal intensive care unit; length of hospital stay.
Economic analysis: cost-effectiveness of FPO to prevent operative delivery for nonreassuring fetal status.
Notes
Sample size calculation: yes, based on reduction in caesarean section rate for nonreassuring fetal status. Fetal oximetry system used: Nellcor OxiFirst. Women's perceptions: results from the first survey are used in this report.
Allocation concealment A -Adequate
Study Garite 2000
Methods Random allocation: telephone randomisation. Quality assessment (see footer): blinding of intervention = C; completeness of follow up = A; blinding of outcome assessment = C. Participants 1189 women in labour. This consisted of 1010 in the published trial and 179 in a pilot of the trial conducted using the same protocol, where unpublished data were accessible.
Inclusion criteria: nonreassuring CTG, >= 36 weeks' gestation, active labour, single fetus, cephalic presentation, cervical dilatation of at least 2 cm and at station -2 or below, ruptured amniotic membranes (or have amniotomy).
Exclusion criteria: planned caesarean section, placenta praevia, need for immediate delivery, active genital herpes or known HIV infection, participation in other studies.
Interventions
Study group: CTG plus fetal pulse oximetry. Protocol for action with reassuring and nonreassuring fetal oximetry values.
Outcomes
Caesarean section for nonreassuring status; caesarean section for all indications; caesarean section for fetal intolerance to labour with dystocia, mixed indication; caesarean dystocia, single indication; spontaneous vaginal delivery; assisted vaginal delivery for nonreassuring fetal status or for all other indications; fetal heart rate patterns; labour interventions and fetal evaluations (eg scalp pH).
Maternal outcomes including: endometritis; length of stay; bleeding; uterine rupture; intrapartum fever.
Notes
Some additional unpublished data from a pilot of the trial, using the same protocol, were available. Further data were requested but were unable to be accessed. Sample size calculation: yes, based on reduction in caesarean section rate for nonreassuring fetal status. Fetal oximetry system used: Nellcor OxiFirst. Inclusion criteria: nonreassuring CTG, >= 28 weeks' gestation, single fetus, cephalic presentation, cervical dilatation of at least 2 cm and at station -5 or below, ruptured amniotic membranes (spontaneous or artificial).
Allocation concealment A -Adequate
Study
Exclusion criteria: planned caesarean section, contraindication to vaginal delivery (including genital herpes, transverse lie), unexplained vaginal bleeding, placenta praevia, ominous CTG requiring immediate delivery, known HIV infection, hepatitis B or C, unable to give consent due to intrapartum parenteral analgesia.
Interventions
Control group: fetal heart rate monitoring (CTG) (Doppler/fetal scalp electrode).
Study group: CTG plus fetal pulse oximetry (Nellcor OxiFirst). Protocol for action with reassuring fetal oximetry (>= 30%) and nonreassuring values (< 30% for 3 minutes).
Outcomes Primary outcome: caesarean section for nonreassuring fetal status.
Maternal outcomes: caesarean section for all indications; caesarean section for dystocia; amnioinfusion and length of labour.
Neonatal outcomes including: Apgar scores; umbilical cord blood gases; resuscitation; admission to neonatal intensive care unit. Notes Further data were requested, awaiting reply.
Sample size calculation: yes, based on reduction in caesarean section rate for nonreassuring fetal status. Fetal oximetry system used: Nellcor OxiFirst.
Allocation concealment B -Unclear
Study Kuhnert 2004
Methods Single-centre, RCT. Random allocation: method not stated and not provided on request. Quality assessment (see footer): blinding of intervention = C; completeness of follow up = A; blinding of outcome assessment = C. Participants 146 women in labour.
Inclusion criteria: CTG with International Federation of Gynecology and Obstetrics (FIGO) score <= 8, gestational age >= 36 weeks, active labour, single fetus, cephalic presentation, cervical dilatation of at least 2 cm and at station -2 or below, ruptured amniotic membranes (or have amniotomy). All cases had FBS prior to randomisation.
Exclusion criteria: planned caesarean section, placenta praevia, need for immediate delivery, active genital herpes or known HIV infection. 
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